Mark Baum is Chief Executive Officer and Chairman of the Board of Directors of Harrow, Inc. (HROW). The company reported total compensation of $23,606,274 for fiscal year 2025.
| Salary | $754,910 |
|---|---|
| Bonus | $0 |
| Stock awards | $22,294,873 |
| Option awards | $0 |
| Non-equity incentive plan | $542,491 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,000 |
| Total | $23,606,274 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Harrow, Inc. filed April 24, 2026, accession 0001493152-26-018912.
| Peer-group chief executive median | $7,522,385 |
|---|---|
| Difference from that median | $16,083,889 |
| Percentile within the disclosed peer group | 99th |
| Peers with a disclosed figure | 11 |
Medians and percentiles are computed across the peer group Harrow, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Baum this page | Chief Executive Officer and Chairman of the Board of Directors | $23,606,274 |
| Andrew Boll | President, Chief Financial Officer and Corporate Secretary | $10,947,441 |
| Amir Shojaei | Chief Scientific Officer | $1,342,627 |
| Francis Mullery | President and Chief Executive Officer, ImprimisRx Division | $1,237,692 |
| John Saharek | Former President and Chief Executive Officer, ImprimisRx Division | $727,421 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Harrow, Inc. compensation brief.
Mark Baum's compensation sits inside Harrow, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.